NPI: 1003367491 · PORTLAND, OR 97232 · General Acute Care Hospital · NPI assigned 10/20/2016
Authorized official JENSEN, SARAH controls 20+ related entities in our dataset. Read more
| Authorized Official | JENSEN, SARAH (VP FINANCE) |
| Parent Organization | LEGACY EMANUEL HOSPITAL & HEALTH CENTER |
| NPI Enumeration Date | 10/20/2016 |
Other providers sharing the same authorized official: JENSEN, SARAH
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 13,221 | $7.26M |
| 2019 | 10,161 | $5.40M |
| 2020 | 11,486 | $5.66M |
| 2021 | 10,375 | $5.61M |
| 2022 | 14,513 | $7.18M |
| 2023 | 13,525 | $10.54M |
| 2024 | 10,152 | $9.15M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| S9484 | Crisis intervention mental health services, per hour | 47,659 | 31,221 | $49.89M |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2,876 | 2,246 | $474K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 18,397 | 15,716 | $307K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 6,502 | 5,791 | $114K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2,171 | 1,890 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 290 | 236 | $3K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 387 | 360 | $2K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 59 | 52 | $1K |
| 80053 | Comprehensive metabolic panel | 2,221 | 1,947 | $1K |
| 84443 | Thyroid stimulating hormone (TSH) | 898 | 817 | $969.01 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 290 | 236 | $763.69 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 87 | 78 | $362.69 |
| 36415 | Collection of venous blood by venipuncture | 1,030 | 883 | $337.21 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 17 | 13 | $267.64 |
| 84703 | 537 | 461 | $71.49 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 12 | 12 | $0.00 |